Metastatic Prostate Tumor Study May Reveal Novel Tailored Treatment Avenues

Metastatic Prostate Tumor Study May Reveal Novel Tailored Treatment Avenues
Researchers at the University of California, Santa Cruz, and the University of California, Los Angeles (UCLA) have identified abnormal signaling pathways in metastatic prostate cancer cells that play a crucial role in tumor cell proliferation and in resistance to androgen-deprivation therapy. Results of the study, "Phosphoproteome Integration Reveals Patient-Specific Networks in Prostate Cancer," published in the journal Cell, also reveal a new computational approach that analyzes patient-specific data and identifies tailored targets for therapy, helping doctors select the most effective drugs for individual patients. "It's like having a blueprint for each tumor. This is our dream for personalized cancer therapy, so we're not just guessing anymore about which drugs will work but can choose drug targets based on what's driving that patient's cancer," Josh Stuart, the Baskin professor of biomolecular engineering at UC Santa Cruz, director of cancer and stem cell genomics at the university's Genomics Institute, and a senior corresponding author of the paper, said in a press release. Identifying the genetic mutations present in cancer cells may improve personalized cancer treatment in the future. But interpreting the data to understand which mutations are actually driving a patient's tumor remains a challenge. Researchers integrated data from genome mutations with data assessing which pathways were active in prostate cancer cells. To do that, they examined the phosphorylation status of each protein. Phosphorylation, which consists of the addition of a phosphate group to specific parts of a protein, is a key step in many signaling pathways as it can activate or deactivate specific proteins. By mapping which proteins had more or less phosphate groups in p
Subscribe or to access all post and page content.